The Manila Times3d
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...
Rheumatology Advisor4d
Denosumab Biosimilars Stoboclo, Osenvelt Get FDA Approval
The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).
Celltrion's Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
Celltrion, Inc., a leading global biopharmaceutical company, announced today that its infliximab biosimilar will be marketed ...
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
Celltrion today announced the U.S. Food and Drug Administration (FDA) approved OMLYCLO® (omalizumab-igec) as the first and ...
Morningstar3d
STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), now available in the United States
Efficacy and Safety after Switch from Reference Ustekinumab to Ustekinumab Biosimilar (CT-P43) in comparison with the Maintenance Group (CTP43 or Reference Ustekinumab) in Patients with Moderate ...
Morningstar4d
Celltrion's Infliximab, the First Monoclonal Antibody Biosimilar, Is Now Remdantry™ in Canada
Patients who have been on Inflectra can continue their therapy without any need to switch between different biosimilars, ensuring consistency in their care during this transition.” Celltrion ...
Pharm Exec6d
FDA Approves Celltrion’s Xolair Biosimilar Omlyclo for Multiple Indications
Omlyclo, a biosimilar to Xolair, is indicated for the treatment of ... or 150 mg doses or Xolair every four weeks for up to 40 weeks. The study also included a switch at week 12, with patients who had ...